Compare Stocks: DNLI, BEAM, BBIO, and EXEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$74.84 -0.8%	$80.74	$48.78 ▼ $93.42	$14.63B	0.97	2.07 million shs	1.54 million shs
BEAM Beam Therapeutics	$29.66 +0.7%	$29.35	$18.72 ▼ $38.26	$3.06B	2.22	1.58 million shs	1.18 million shs
DNLI Denali Therapeutics	$22.28 -2.3%	$24.44	$12.58 ▼ $27.30	$3.64B	1.01	1.18 million shs	799,584 shs
EXEL Exelixis	$59.01 -0.2%	$55.07	$33.76 ▼ $59.72	$14.62B	0.42	2.26 million shs	1.58 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.76%	-2.30%	-8.72%	+10.69%	+44.37%
BEAM Beam Therapeutics	+0.68%	+1.16%	+9.57%	+0.88%	+58.10%
DNLI Denali Therapeutics	-2.28%	-7.17%	-8.76%	+14.14%	+45.53%
EXEL Exelixis	-0.20%	+8.37%	+4.07%	+11.97%	+59.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$74.84 -0.8%	$80.74	$48.78 ▼ $93.42	$14.63B	0.97	2.07 million shs	1.54 million shs
BEAM Beam Therapeutics	$29.66 +0.7%	$29.35	$18.72 ▼ $38.26	$3.06B	2.22	1.58 million shs	1.18 million shs
DNLI Denali Therapeutics	$22.28 -2.3%	$24.44	$12.58 ▼ $27.30	$3.64B	1.01	1.18 million shs	799,584 shs
EXEL Exelixis	$59.01 -0.2%	$55.07	$33.76 ▼ $59.72	$14.62B	0.42	2.26 million shs	1.58 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.76%	-2.30%	-8.72%	+10.69%	+44.37%
BEAM Beam Therapeutics	+0.68%	+1.16%	+9.57%	+0.88%	+58.10%
DNLI Denali Therapeutics	-2.28%	-7.17%	-8.76%	+14.14%	+45.53%
EXEL Exelixis	-0.20%	+8.37%	+4.07%	+11.97%	+59.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.83	Moderate Buy	$101.53	35.66% Upside
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	65.21% Upside
DNLI Denali Therapeutics	2.76	Moderate Buy	$35.85	60.89% Upside
EXEL Exelixis	2.35	Hold	$50.07	-15.16% Downside

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, BBIO, and EXEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/2/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/1/2026	BBIO BridgeBio Pharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$96.00 ➝ $110.00
9/1/2026	EXEL Exelixis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/25/2026	DNLI Denali Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $35.00
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/12/2026	BBIO BridgeBio Pharma	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$102.00 ➝ $107.00
8/12/2026	BBIO BridgeBio Pharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $106.00
8/12/2026	BBIO BridgeBio Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$100.00 ➝ $111.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$713.07M	20.52	N/A	N/A	($12.81) per share	-5.84
BEAM Beam Therapeutics	$156.04M	19.63	N/A	N/A	$10.34 per share	2.87
DNLI Denali Therapeutics	$3.60M	988.18	N/A	N/A	$5.22 per share	4.27
EXEL Exelixis	$2.44B	6.00	$3.02 per share	19.53	$7.44 per share	7.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.56	15.91	1.76	35.33%	42.17%	31.76%	11/3/2026 (Estimated)

Latest DNLI, BEAM, BBIO, and EXEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	$0.90	3.03%	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	1.23	1.17
BEAM Beam Therapeutics	0.09	14.57	14.57
DNLI Denali Therapeutics	0.01	8.37	8.32
EXEL Exelixis	N/A	3.46	3.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BEAM Beam Therapeutics	99.68%
DNLI Denali Therapeutics	92.92%
EXEL Exelixis	85.27%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
BEAM Beam Therapeutics	3.80%
DNLI Denali Therapeutics	9.70%
EXEL Exelixis	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	195.49 million	167.67 million	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
DNLI Denali Therapeutics	430	159.85 million	144.34 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable

DNLI, BEAM, BBIO, and EXEL Headlines

Recent News About These Companies

Exelixis, Inc. $EXEL Shares Sold by Three Seasons Wealth LLC

September 5 at 5:35 AM | marketbeat.com

IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out

September 4 at 1:31 PM | investors.com

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

September 4 at 12:37 PM | zacks.com

What is Zacks Research's Estimate for Exelixis Q4 Earnings?

September 4 at 6:56 AM | marketbeat.com

Exelixis (NASDAQ:EXEL) Reaches New 52-Week High Following Analyst Upgrade

September 4 at 4:00 AM | americanbankingnews.com

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

September 3 at 10:41 AM | zacks.com

Exelixis (NASDAQ:EXEL) Stock Rating Upgraded by Zacks Research

September 3 at 6:05 AM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Exelixis, Inc. $EXEL

September 3 at 5:03 AM | marketbeat.com

Cancer stock breaks out to highs; key FDA action on watch

September 2 at 6:26 PM | msn.com

Exelixis (NASDAQ:EXEL) Sets New 12-Month High - Still a Buy?

September 2 at 10:59 AM | marketbeat.com

Exelixis, Inc. $EXEL Shares Sold by Corient Private Wealth LP

September 2 at 3:44 AM | marketbeat.com

Exelixis, Inc. (NASDAQ:EXEL) Receives $50.07 Average PT from Analysts

September 2 at 1:59 AM | americanbankingnews.com

Cancer Drug Patent Claims Upheld by CAFC

September 1, 2026 | ipwatchdog.comI

Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data

September 1, 2026 | seekingalpha.com

Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data

September 1, 2026 | seekingalpha.com

Exelixis Wins Appeal in Patent Case Against MSN Laboratories

September 1, 2026 | finance.yahoo.com

Corient Private Wealth LP Takes $4.32 Million Position in Exelixis, Inc. $EXEL

September 1, 2026 | marketbeat.com

Exelixis Secures Key Patent Victory, Extends Exclusivity

August 31, 2026 | tipranks.com

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

August 31, 2026 | businesswire.com

Jefferies Financial Group Inc. Lowers Position in Exelixis, Inc. $EXEL

August 31, 2026 | marketbeat.com

Hsbc Holdings PLC Makes New $2.59 Million Investment in Exelixis, Inc. $EXEL

August 31, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, BBIO, and EXEL Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$74.84 -0.57 (-0.76%)

As of 09/4/2026 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Beam Therapeutics NASDAQ:BEAM

$29.66 +0.20 (+0.68%)

As of 09/4/2026 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$22.28 -0.52 (-2.28%)

As of 09/4/2026 04:00 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Exelixis NASDAQ:EXEL

$59.01 -0.12 (-0.20%)

As of 09/4/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, BBIO, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNLI, BEAM, BBIO, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNLI, BEAM, BBIO, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, BBIO, and EXEL Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Beam Therapeutics NASDAQ:BEAM

Denali Therapeutics NASDAQ:DNLI

Exelixis NASDAQ:EXEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, BBIO, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNLI, BEAM, BBIO, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNLI, BEAM, BBIO, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, BBIO, and EXEL Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Beam Therapeutics NASDAQ:BEAM

Denali Therapeutics NASDAQ:DNLI

Exelixis NASDAQ:EXEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools